Advertisement
Home 2015

Archives

Almost a third of U.S. children with attention-deficit/hyperactivity disorder were diagnosed before the age of 6

One-Third of U.S. Children With ADHD Diagnosed Before Age 6

0
But researchers add that few valid tests exist to support diagnosis in children that young
Varubi (rolapitant) has been approved by the U.S. Food and Drug Administration to prevent delayed phase chemotherapy-induced nausea and vomiting.

FDA Approves Varubi for Chemo-Induced Nausea, Vomiting

0
For prevention of the delayed phase of nausea, vomiting caused by chemotherapy
The U.S. smoking rate continues to decline

CDC: Smoking Rate Falls to 15.2 Percent in the United States

0
Higher tobacco taxes, tough messages contributing to decline
Use of dipeptidyl peptidase-4 inhibitors in type 2 diabetes is tied to severe joint pain in some patients

FDA Warns of Joint Pain Tied to DPP-4 Inhibitors

0
Agency advises users with such symptoms to contact their doctor
The outcome of a recent case regarding the termination of physicians by an insurance company following a dispute over the necessity of medical services provided has serious implications for physicians and their patients

AMA: Ruling Makes It Easier for Insurers to Terminate Doctors

0
Court supported insurance company in termination of doctors after dispute over necessity of services
Repatha (evolocumab) has been approved by the U.S. Food and Drug Administration

FDA Approves Repatha for Certain Patients With High Cholesterol

0
Approved for patients unable to get LDL cholesterol under control with current treatment options
A proposal for identifying lower-cost generic biotech drugs has been released by the U.S. Food and Drug Administration.

FDA Issues Proposal on Lower-Cost, Generic Biotech Drugs

0
All biotech drugs to carry a four-letter code to distinguish brand name, generic versions
About 17.5 percent of U.S. children aged 3 to 19 are obese

CDC: Rates of Childhood Obesity Higher in U.S. Than Canada

0
Rates differ dramatically for children aged 7 to 12
The American Academy of Dermatology has published a second list of recommendations regarding dermatologic tests and treatments that are not always necessary.

AAD Issues 2nd Set of Choosing Wisely Recommendations

0
American Academy of Dermatology identifies five tests, treatments that are not always necessary
U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children 1 year and older with chronic immune thrombocytopenic purpura.

Promacta Approval Expanded for Children With Chronic ITP

0
Builds on recent approval for ages 6 years and up for chronic immune thrombocytopenic purpura